Background: There are case reports and small series in the literature relating to the use of medicinal leeches by plastic surgeons; however, larger series from individual units are rare. The aim of this article is to present a comprehensive 4-year case series of the use of medicinal leeches, discuss the current evidence regarding indications, risks, and benefits and highlight the recent updates regarding leech speciation. Methods: Patients prescribed leeches in a 4-year period (July 2004(July -2008 were collated from hospital pharmacy records (N 5 35). The number of leeches used, demographic, clinical, and microbiological details were retrospectively analyzed. Results: Thirty-five patients were treated with leeches. The age range was 2 to 98 years (mean 5 49.3). Leeches were most commonly used for venous congestion in pedicled flaps and replantations. Blood transfusions were necessary in 12 cases (34%) [mean 5 2.8 units, range 2-5 units]. Our infection rate was 20% (7/35) including five infections with Aeromonas spp. (14.2%). The proportion of patients becoming infected after leech therapy was significantly greater in the group of patients that did not receive prophylactic antibiotic treatment (Fisher's Exact test P 5 0.0005). In total, 14 cases (40%) were salvaged in entirety, in 7 cases 80% or more, in 2 cases 50 to 79%, and in 1 case less than 50% of the tissues were salvaged. In 11 cases (31%), the tissues were totally lost. Conclusion: Our study highlights both the benefits and the risks to patients in selected clinical situations and also the potential risks. The routine use of antibiotic prophylaxis is supported. In view of the emerging evidence that Hirudo verbana are now used as standard leech therapy, and the primary pathogen is Aeromonas veronii, until a large prospective multicenter study is published, large series of patients treated with leeches should be reported. V V C 2011 Wiley-Liss, Inc. Microsurgery 31:281-287, 2011.
Medicinal leech therapy is currently drawing both highprofile public and scientific attention as novel indications are explored for this ancient treatment. 1 The early success of leech therapy in plastic and reconstructive surgery 2 and, more recently, its effectiveness in treating chronic pain syndromes associated with degenerative diseases 3 have helped leech therapy gain acceptance in modern clinical medicine. 4 The Food and Drug Administration of the United States only recently approved the use of the leech as a medical device. 5 The medicinal leech, Hirudo medicinalis, is protected internationally by its listing on appendix II of the Convention on International Trade in Endangered Species of Wild Fauna and Flora and in the United Kingdom specifically under Schedule 5 of the Wildlife and Countryside Act 1981. Most commercial suppliers still market medicinal leeches as H. medicinalis; however, a recent study revealed that many leeches sold were genetically distinct from H. medicinalis and identified as H. verbana. 6 The predominance of H. verbana is likely due to overharvesting of H. medicinalis in the 19th century at the peak of their popularity and the loss of wetlands.
These two different types of leech can be distinguished based on differences in color patterns on their dorsal and ventral body surfaces. Some authors are encouraging the use of ''DNA Barcodes'' such as cytochrome oxidase I (COI) gene sequences to reveal genetic variations in different types of leeches 7 as there can be a wide variation in physical appearance. Clarification of these differences with regard to medical or microbiological differences will continue over the coming years.
Early attempts to characterize the digestive tract microbiota were limited by their purely culture-based approach. It is now widely recognized that around 99% of microbes are presently unculturable. 8 Recent studies have indicated that differences exist in the microbial communities of Hirudo verbana and Hirudo orientalis.
9,10
The microbial community of Hirudo medicinalis is currently under investigation with similar advanced techniques. Current studies are ongoing to elucidate the differences between the anticoagulant profiles of different Hirudo species.
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The use of leeches by plastic surgeons to aid salvage of compromised microvascular free-tissue transfers, 12, 13 venously congested digits, [14] [15] [16] nipples, 17 ears, 18 lips, literature relating to the use of medicinal leeches in plastic surgery; however, larger series from individual units with clinical analysis are rare. 22 In this article, we present a comprehensive 4-year case series of the use of medicinal leeches in a plastic surgery centre and discuss the current thinking with regard to indications, risks, and benefits.
METHODS
The hospital numbers and dates of birth of all patients prescribed leeches in the 4-year period (July 2004-July 2008) were collated from hospital pharmacy records (N 5 35). Using this information, the hospital notes were retrieved and both demographic and clinical details were retrospectively analyzed. Using the patients' hospital numbers, the medical notes and microbiology database were accessed, and all transfusion requirements, swab results, and antibiotic treatments for the ''leech episode'' were documented. The total number of leeches used over the same 4-year period (July 2004-July 2008) was also collated from pharmacy records. From this data, the total financial cost per year was calculated.
The proportion of patients becoming infected as a result of leech therapy was compared between the group of patients that did not receive prophylactic antibiotic treatment and the group that did. A two-sided P value was calculated using Fisher's test with GraphPad prism software. were females, and the remaining 18 (51%) were male. There was a wide range of indications for treatment (See Fig. 1 2a ) and only once was it started on day 4. None of the patients included in the study underwent surgical re-exploration for venous congestion and, no venous supercharging procedures were performed before leech therapy. The average length of leech treatment was 5.6 days (range 1-13 days) (See Fig. 2b ). Blood transfusions were necessary in 12 cases (34%) [mean 5 2.8, range 2-5 units] (See Fig. 2c) . In our series, we encountered an infection rate of 20% (7/ 35) including five infections with Aeromonas hydrophila (14.2%). Of note, all five isolates of Aeromonas were sensitive to ciprofloxacin. Antibiotic prophylaxis was highly variable depending on the consultant in charge. Only 16 of 35 patients (46%) received antibiotic prophylaxis (4 co-amoxiclav, 6 ciprofloxacin, 3 co-amoxiclav and ciprofloxacin, 1 metronidazole and co-amoxiclav, 1 cefuroxime, and 1 flucloxacillin and phenoxymethylpenicillin). The proportion of patients becoming infected after leech therapy was significantly greater in the group of patients that did not receive a prophylactic antibiotic treatment compared with the group of patients who did receive antibiotic prophylaxis (26% vs. 12.5%, Fisher's exact test P 5 0.0005). Of the seven infected cases, one case of Pseudomonas spp. infection was successfully treated with ciprofloxacin resulting in 80% salvage, one infection with methicillin-resistant Staphylococcus aureus resulted in 100% flap loss, two cases of infection due to Aeromonas hydrophila were successfully treated with ciprofloxacin resulting in a 100% salvage rate, one infection with Aeromonas hydrophila was treated with augmentin resulting in 90% salvage, and two cases of Aeromonas infection contributed to complete flap loss. Our infection rate with Aeromonas spp. was 14.2% (5/35), with a salvage rate of 60% (3/5). The identification of the wound isolates was performed in a clinical diagnostic laboratory. Because of the difficulties of identifying Aeromonads and the inaccuracies of commercial kits to identify especially environmental isolates, these identifications may not be accurate but reflect the information given to the treating physicians.
RESULTS

Our
In total following leech therapy, 14 cases (40%) were salvaged in entirety; in 7 cases, 80% or more of the tissue was salvaged; in 2 cases, 50 to 79% of the flap was salvaged; in one case, more than 50% of the flap was lost, and, in 11 cases (31%), the tissues were totally lost (See Fig. 2d ).
In the management of congested replanted digits, we salvaged 7 of 10 cases (70%) in our series (See Table 1 ). Additionally, we were able to salvage >90% of the flap surface area in 77% of our cutaneous pedicled flaps, which were exhibiting signs of venous congestion postoperatively (See Table 1 ). In free-tissue transfers, there was a 100% loss despite the use of leeches in all four cases of venous congestion (See Table 1 ).
The number of leeches to be used depends on the volume of the congested tissue. On a digital replant, for example, two leeches are sufficient, whereas larger pedicled flaps may need as many as five or six leeches. ; and replantations, which Foucher so clearly defined in 1981. 23 For these indications, with appropriate antibiotic prophylaxis, we believe leeches should always be considered in the absence of the relative contraindications outlined below.
Tamai, 24 when reporting on his 20-year experience of over 290 replantations, stated that there was only a 17% salvage rate in replanted digits exhibiting venous congestion postoperatively. He never used leeches. Foucher et al., when using leeches routinely, recorded an overall salvage rate of 55-60 percent. 23 These figures are comparable to our figures (70%) (See Table 1 ). The unsuccessful replants tended to be those with either a crush component to the initial soft tissue injury or degloving injuries. Although it is impossible to prove beyond doubt, in our clinical opinion, without the use of leeches, some of these replants would have failed.
The salvage rate of our pedicled cutaneous flaps (77%) was comparable with the salvage rate of 70% described by Derganc and Zdravic 2 in their seminal paper on the subject.
Although we believe their clinical utility is beyond doubt, leeches are not the answer for all postoperative problems. This has proven to be the case mainly in the treatment of congested free-tissue transfers. Our experience in using leeches on free Deep Inferior Epigastric artery Perforator (DIEP) flaps was poor. This further reinforces the notion that in free flaps developing a problem with venous drainage, the treatment of choice should be re-exploration of the anastomosis if at all possible. In our free flap cases, this was not performed due to a combination of both patient and technical factors. Recent experimental evidence suggests that venous supercharging by using additional routes of venous drainage can have a statistically significant benefit with a correlation shown between the number of venous outflow routes and survival of free flaps and reduction in the incidence of venous congestion. 25, 26 A recent retrospective review of 564 consecutive DIEP flaps at a single institution showed that the use of a secondary vein in the drainage of a DIEP flap can significantly reduce the incidence of venous congestion without any significant effect on the incidence of complete flap failure and overall takebacks. 27 They also demonstrated that the use of a secondary vein does not significantly increase operative times. Although initial results are promising, further large clinical studies are needed to demonstrate the benefits of venous supercharging procedures in free-tissue transfers.
Relative Contraindications
These include arterial insufficiency, immunosuppression, patients with a bleeding diathesis, Jehovah's witnesses, 28 those who have previously exhibited allergy to leeches or their foreign proteins, 29 and individuals with a psychological aversion to the annelid's use. 22 Those with diabetes and smokers in particular should be counselled on the theoretical increased risks of infection and treatment failure.
Start of Treatment
Leech therapy was started in the first 48 hours 91% of the time. There was no relationship between the commencement of leech therapy and outcome. It has been postulated that leech therapy should be commenced at the earliest sign of outflow compromise, 22 although to our knowledge there has been no definitive proof that a reasonable delay in application affects outcome.
Length of Treatment
In our series, the average length of leech treatment was 5.6 days (range 1-13 days). (See Fig. 2b ) It is evident that when leeches are the only source of venous outflow leech treatment should be continued until inosculation occurs. On the basis of experimental animal models, this process needs 3 to 5 days; however, limited clinical data suggests that 6 to 10 days are necessary. 30 A previous meta-analysis has quoted the average leech therapy to be 4.2 days. 22 
Number and Timing of Leech Application
In general, the volume of leeches used per plastic surgery unit per unit time, and the number of leeches used per patient reflects enormous diversity of opinion and practice, and there is little in the literature studying this. Over the period from 2004 to 2008, the use of leeches peaked at 858 leeches in 2006 with a peak cost of £9221 per financial year. It is unclear whether a reduction in the number of leeches used would reduce the cost, infection rates, and transfusion requirements while maintaining clinical outcomes. There is little doubt that the cost of ''leeching'' is likely to be cheaper than additional revisional surgery necessary in the absence of leeching.
In our experience, leeches should be applied every 6 hours, as evidence from the literature shows that over 90% of passive bleeding occurs within 5 hours. This 6 hourly application time allows for feeding and passive bleeding. A commonly asked question is how many leeches to use and how often. There is no clarity in the literature regarding this question, and a wide variety of regimes have been used. It is impossible to assess accurately the number of leeches used per patient and the timing of application, as this was not stringently logged on a patient by patient basis. Greater numbers of leeches are likely to require high-dependency unit admission, regular hemoglobin checks and blood transfusions.
Transfusion Requirements
Persistent and prolonged bleeding after the removal of the leech has long been considered a complication. In 1819, White reported that a 2-year-old girl had died due to excessive blood loss induced by a single leech. 31 Although adverse events associated with blood transfusions are improving, they still cause morbidity and mortality in both adult 32 and pediatric populations. 33 In our experience, blood transfusions were necessary in 12 cases (34%) [mean 5 2.8 units, range 2-5 units]. All four of the DIEP flap patients required blood transfusions and none of the replantations. Clearly, the need for transfusion will depend on patients' comorbidities and the nature of the operative intervention; however, the use of leeches certainly potentiates bleeding risk. As stated by Lineweaver et al., 16 the application of leeches to replants is a different situation to that of free-tissue transfers. Restoring circulation in these tissues by exsanguinations is likely to result in a prohibitive amount of blood loss. To support this argument, 100% transfusion requirements have been reported by Chepeha et al. 34 in a small series of head and neck free-tissue transfers salvaged with leeches and intensively monitored in Michigan. These patients required an average of 13 units (range 5-28 units). Transfusion requirements of up to 78 units have been reported in some units. 35 In his meta-analysis, Chaplain suggested a 66% requirement for blood transfusion (mean 5 4.4 units). Problematic bleeding in the majority of cases can be well controlled with direct pressure and topical thrombin. It is sensible to keep a daily check on the hemoglobin during leech therapy, particularly in young children. 36 Previous studies have shown that any combination of anticoagulant therapy in addition to the use of leeches leads to a substantial increase in the need for blood transfusion. 37 
Infection
The plastic surgery community has been aware of the infection risk associated with leech application since it was first reported in the British Medical Journal by Dickson, 38 and, then 3 years later, when it was discussed by Whitlock in the British Journal of Plastic Surgery.
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Since then, a high incidence of infection during and after application of medicinal leeches has been widely reported despite external decontamination. The exact incidence of leech-associated infection associated with postoperative use is difficult to assess, with incidences ranging from 2.4% to 36.2% being reported in the literature. 39, 40 Despite several publications advocating prophylactic antibiotics to combat leech-borne infections, 16, 41 many units either do not use antibiotic prophylaxis at all or continue to use less effective agents. 36 The leech bite, created by three jaws, each containing 60 to 100 pairs of cutting teeth, forms a characteristic Y-shaped triradiate conformation 1 mm in diameter and up to 1.5 mm in depth. 42 The combination of local tissue damage, along with contact between the oral and digestive tract flora, and the patient allows the potential for infection. Extensive studies have been carried out on the surface, mouth, and digestive-tract microbiota of leeches, 8, 41, 43 which show Aeromonas spp. to be prominent in the resident flora. The venous congestion in plastic surgery patients leads to a localized area of immunocompromise that is more susceptible to infection. The most common clinical presentation is of cellulitis 44 and, in severe cases, extensive tissue loss and septicemia has been reported. 45 Aeromonas seems to have an affinity for muscle tissue, and is capable of producing extensive proteolytic enzymes leading to a picture resembling clostridial myonecrosis with gas production. 46 The ability of Aeromonas to invade the walls of blood vessels with resultant vasculitis, thrombosis, and hemorrhagic necrosis is of most concern to microsurgeons.
Over the 4-year study period, there were seven cases of infection post leech therapy. Our infection rate with Aeromonas spp. was 14.2% (5/35), with a salvage rate of 60% (3/5) (See Table 1 ). This is a satisfactory salvage rate considering the meta-analysis by de Chalain et al. 22 reporting on a clinical series of replants, free and pedicled flaps. His study reported a drop in the salvage rate of tissues from an expected 60-80% to 31.8% in infected tissues. Most authors in this analysis reported a complete loss of infected tissues. Aeromonas infections typically require treatment with aggressive debridement and antibiotic therapy, and this practice was followed in our series. Seminal microbiological studies by Lineweaver et al. 41, 47 show that in patients receiving prophylactic quinolones, there were significant decreases in leech enteric bacterial cultures.
In our clinical series, the proportion of patients becoming infected after leech therapy was significantly greater in the group of patients that did not receive a prophylactic antibiotic treatment (Fisher's exact test P 5 0.0005).
Despite the emerging evidence, high levels of resistance to first generation cephalosporins, penicillins (via b-lactamases), tetracyclines, and augmentin have been observed in studies, 48 with fluoroquinoles seeming to be consistently active. 49 Even new and widely used textbooks 50 continue to advocate the use of potentially ineffective agents such as amoxicillin and clavulanic acid preparations (co-amoxiclav). Our experience and those of others suggest that prophylactic fluoroquinolones seem to be mandatory given the preponderance of infection.
CONCLUSION
Despite the widespread use of leeches worldwide, we believe that there are insufficient prospective studies with large enough numbers to inform the microsurgical specialist on outcomes from leech usage and the risks and benefits for each indication. Our future research efforts will involve an interdisciplinary prospective multicenter study combining genetic clarification of leech types, hematological parameters, outcome analysis, and isolates from surgical wounds.
